Many antibody discovery campaigns still measure success by the number of binders recovered, but high hit count alone does not guarantee functional, developable, or differentiated lead candidates. How should teams define success earlier in the campaign?

Discovery strategy increasingly requires thoughtful integration of immunization, in vitro display, single B cell screening, functional assays, and developability profiling. When should teams prioritize breadth and diversity versus deeper early functional characterization?

Early functional screening can improve lead quality, but it also adds complexity, cost, and operational risk. What are the right decision points for adding functional assays, counter-screens, cross-reactivity screens, and developability filters?

As AI-enabled design and high-throughput screening expand the number of molecules that can be generated, how do discovery teams avoid scaling noise and instead preserve the biological insight needed to nominate better leads?